U.S. Markets close in 4 hrs 15 mins
  • S&P 500

    3,993.28
    -32.84 (-0.82%)
     
  • Dow 30

    34,091.07
    -255.96 (-0.75%)
     
  • Nasdaq

    11,138.46
    -87.90 (-0.78%)
     
  • Russell 2000

    1,848.00
    -21.19 (-1.13%)
     
  • Crude Oil

    75.87
    -0.41 (-0.54%)
     
  • Gold

    1,743.00
    -11.00 (-0.63%)
     
  • Silver

    20.96
    -0.47 (-2.19%)
     
  • EUR/USD

    1.0382
    -0.0023 (-0.2180%)
     
  • 10-Yr Bond

    3.7000
    +0.0090 (+0.24%)
     
  • Vix

    21.90
    +1.40 (+6.83%)
     
  • GBP/USD

    1.2037
    -0.0053 (-0.4394%)
     
  • USD/JPY

    138.7490
    -0.3510 (-0.2523%)
     
  • BTC-USD

    16,173.06
    -397.41 (-2.40%)
     
  • CMC Crypto 200

    378.85
    -1.44 (-0.38%)
     
  • FTSE 100

    7,481.28
    -5.39 (-0.07%)
     
  • Nikkei 225

    28,162.83
    -120.20 (-0.42%)
     

Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences Inc.
Solid Biosciences Inc.

CHARLESTOWN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Co-Founder, President and CEO, and Carl Morris, Ph.D., Chief Scientific Officer, will participate at the following two upcoming investor conferences:

  • Jefferies Cell and Genetic Medicine Summit – New York, NY
    Fireside chat on Friday, September 30, 2022 at 3:00 PM ET.

  • Chardan’s 6th Annual Genetic Medicines Conference – New York, NY
    Fireside chat on Tuesday, October 4, 2022 at 1:00 PM ET.

A live webcast of these presentations will be available on the Company’s investor relations website, under the Events page accessible here: https://investors.solidbio.com/news-and-events/events. A replay will be available on the Company's website following the events.

About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our gene therapy candidates, SGT-001 and SGT-003. For more information, please visit www.solidbio.com.

Investor Contacts:
Caitlin Lowie
Solid Biosciences
607-423-3219
Clowie@solidbio.com

David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com

Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com